EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin

Schafer Boeder iD, Michael J Davies, Janet B McGill iD, Richard Pratley, Manon Girard, Phillip Banks, Jeremy Pettus, Satish Garg

Diabetes Technology & Therapeutics · 2024

DOI: 10.1089/dia.2023.0605 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Technology & Therapeutics, 2024. Verfasst von Schafer Boeder und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Diabetes Mellitus, Type 1, 3-Hydroxybutyric Acid, Glycosides. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sodium glucose cotransporter inhibitors may increase beta-hydroxybutyrate (BHB) in insulin-requiring patients. We determined factors associated with BHB changes from baseline (ΔBHB) and diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D) receiving sotagliflozin as an insulin adjunct. Research Design and Methods: This post hoc analysis compared ΔBHB levels in adults with T1D receiving sotagliflozin 400 mg or placebo for 6 months. We evaluated clinical and metabolic factors associated with ΔBHB and used logistic regression models to determine predictors associated with BHB values >0.6 and >1.5 mmol/L (inTandem3 population; N = 1402) or with DKA events in a pooled analysis (inTandem1–3; N = 2453).

Results

From baseline (median, 0.13 mmol/L), median fasting BHB increased by 0.04 mmol/L (95% confidence interval, 0.03–0.05; P < 0.001) at 24 weeks with sotagliflozin versus placebo; 67% of patients had no or minimal changes in BHB over time. Factors associated with on-treatment BHB >0.6 or >1.5 mmol/L included baseline BHB and sotagliflozin use. Age, insulin pump use, sotagliflozin use, baseline BHB, and ΔBHB were significantly associated with DKA episodes. Independent of treatment, DKA risk increased by 18% with each 0.1-mmol/L increase in baseline BHB and by 8% with each 0.1-mmol/L increase from baseline.

Conclusion

Incremental increases in baseline BHB and ΔBHB were associated with a higher DKA risk independent of treatment. Adding sotagliflozin to insulin increased median BHB over 24 weeks in patients with T1D and was associated with increased DKA events. These results highlight the importance of BHB testing and monitoring and individualizing patient education on DKA risk, mitigation, identification, and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic KetoacidosisDiabetes Mellitus, Type 13-Hydroxybutyric AcidGlycosidesSodium-Glucose Transporter 2 InhibitorsInsulinHypoglycemic AgentsHumansMaleFemaleAdultMiddle AgedDouble-Blind MethodRisk FactorsBlood Glucose

Stichwörter der Autor:innen

Beta-hydroxybutyrateDiabetic ketoacidosisSGLT-2/SGLT-1 inhibitorsSotagliflozinType 1 diabetes

Substanzen

3-Hydroxybutyric AcidGlycosides(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triolSodium-Glucose Transporter 2 InhibitorsInsulinHypoglycemic AgentsBlood Glucose

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
  • Division of Endocrinology, Metabolism and Lipid Research, John T. Milliken Department of Medicine, Washington University, St. Louis, Missouri, USA.
  • AdventHealth Translational Research Institute, Orlando, Florida, USA.
  • Barbara Davis Center for Diabetes at the University of Colorado Denver, Aurora, Colorado, USA.

ORCID-Profile: Schafer Boeder, Janet B McGill

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Boeder, S., Davies, M. J., McGill, J. B., Pratley, R., Girard, M., Banks, P., Pettus, J., & Garg, S. (2024). Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0605

Vancouver

Boeder S, Davies MJ, McGill JB, Pratley R, Girard M, Banks P, et al. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technology & Therapeutics. 2024. doi:10.1089/dia.2023.0605

BibTeX
@article{Boeder2024,
  author = {Boeder, Schafer and Davies, Michael J and McGill, Janet B and Pratley, Richard and Girard, Manon and Banks, Phillip and Pettus, Jeremy and Garg, Satish},
  title = {Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin},
  journal = {Diabetes Technology & Therapeutics},
  year = {2024},
  doi = {10.1089/dia.2023.0605}
}
Kostenlos starten →